Wealthfront Advisers
ABBV icon

Wealthfront Advisers’s AbbVie ABBV Stock Holding History

Wealthfront Advisers’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.8M Buy
182,934
+2,931
+2% +$650K 0.09% 87
2025
Q4 		$41.1M Buy
180,003
+4,603
+3% +$1.05M 0.09% 78
2025
Q3 		$40.6M Buy
175,400
+14,845
+9% +$3.02M 0.1% 76
2025
Q2 		$29.8M Sell
160,555
-268
-0.2% -$49.8K 0.08% 86
2025
Q1 		$33.7M Buy
160,823
+11,726
+8% +$2.28M 0.09% 73
2024
Q4 		$26.5M Buy
149,097
+9,608
+7% +$1.77M 0.08% 80
2024
Q3 		$27.5M Buy
139,489
+5,380
+4% +$1M 0.08% 70
2024
Q2 		$23M Sell
134,109
-3,744
-3% -$620K 0.08% 76
2024
Q1 		$25.1M Buy
137,853
+6,615
+5% +$1.14M 0.09% 67
2023
Q4 		$20.3M Sell
131,238
-11,104
-8% -$1.62M 0.08% 69
2023
Q3 		$21.2M Buy
142,342
+16,107
+13% +$2.36M 0.09% 68
2023
Q2 		$17M Sell
126,235
-57,358
-31% -$8.41M 0.07% 74
2023
Q1 		$29.3M Sell
183,593
-2,081
-1% -$318K 0.13% 47
2022
Q4 		$30M Buy
185,674
+12,451
+7% +$1.91M 0.15% 45
2022
Q3 		$23.2M Buy
173,223
+8,913
+5% +$1.28M 0.12% 44
2022
Q2 		$25.2M Buy
164,310
+23,252
+16% +$3.55M 0.13% 42
2022
Q1 		$22.9M Buy
141,058
+13,043
+10% +$1.89M 0.1% 46
2021
Q4 		$17.3M Buy
128,015
+10,538
+9% +$1.24M 0.07% 62
2021
Q3 		$12.7M Buy
117,477
+15,313
+15% +$1.75M 0.06% 66
2021
Q2 		$11.5M Buy
102,164
+9,608
+10% +$1.08M 0.05% 62
2021
Q1 		$10M Buy
92,556
+3,997
+5% +$428K 0.05% 62
2020
Q4 		$9.49M Sell
88,559
-7,449
-8% -$716K 0.06% 59
2020
Q3 		$8.41M Sell
96,008
-8,382
-8% -$789K 0.06% 63
2020
Q2 		$10.2M Buy
104,390
+15,628
+18% +$1.38M 0.08% 44
2020
Q1 		$6.76M Buy
88,762
+18,730
+27% +$1.6M 0.06% 53
2019
Q4 		$6.2M Buy
70,032
+6,862
+11% +$570K 0.05% 68
2019
Q3 		$4.78M Buy
63,170
+5,492
+10% +$377K 0.04% 74
2019
Q2 		$4.19M Sell
57,678
-4,222
-7% -$332K 0.04% 80
2019
Q1 		$4.99M Sell
61,900
-28,507
-32% -$2.33M 0.05% 73
2018
Q4 		$8.34M Buy
+90,407
New +$7.95M 0.09% 44

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wealthfront Advisers's ABBV Position: Q1 2026 in Review

Wealthfront Advisers increased its AbbVie (ABBV) stake by 1.6% in Q1 2026, buying an estimated $650K and bringing the position to 182,934 shares worth $39.8M. The position accounts for 0.09% of the portfolio, ranked #87.

Wealthfront Advisers first reported a position in ABBV in Q4 2018 and has held it in 30 quarters since. The position peaked at $41.1M in Q4 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Wealthfront Advisers held 182,934 shares of AbbVie worth $39.8M as of Q1 2026.
  • Wealthfront Advisers bought 2,931 AbbVie shares in Q1 2026, an estimated $650K.
  • AbbVie made up 0.09% of Wealthfront Advisers's portfolio in Q1 2026, its #87 holding.
  • Wealthfront Advisers first reported a position in AbbVie in Q4 2018 and has held it in 30 quarters since.
  • Wealthfront Advisers's AbbVie position peaked at $41.1M in Q4 2025.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Wealthfront Advisers's 13F filing for Q1 2026, filed 5 May 2026.